Study identifies immune changes linked to refractory MG
A new study reveals a distinct immune signature associated with difficult-to-treat MG that may lead to new treatment targets.
News
-
-
COVID vaccine does not make MG worse, study finds
A recent review found that COVID-19 vaccination lowers the risk of infection and does not exacerbate myasthenia gravis symptoms.
-
New review outlines safer pregnancy planning for women with MG
Controlling symptoms of myasthenia gravis before conception is key to achieving the best possible outcomes, researchers say.
-
Efgartigimod found effective in ocular MG, argenx shares
Findings from the phase 3 ADAPT OCULUS trial demonstrated the safety and efficacy of efgartigimod alfa and hyaluronidase-qvfc in ocular MG.
-
Smoking increases risk of conversion from ocular to generalized MG
Researchers described a number of factors, chief among them smoking, were associated with conversion from ocular to generalized MG.
-
Feeling understood by others linked to better mental wellbeing in MG
MG fatigue leads to worse daily functioning and quality of life, but feeling that others understand this fatigue can help.
-
Study suggests Descartes-08 may offer long-term benefits in MG
A single course of Descartes-08 was found safe and resulted in long-term symptom improvement in patients with generalized MG.
-
FDA grants priority review to efgartigimod for seronegative MG
The FDA accepted priority review for a supplemental Biologics License Application for the therapy in AChR-antibody seronegative generalized MG.
-
Study finds urinary dysfunction is common in MG
A recent study study found a higher burden of urinary symptoms in patients with MG, particularly in those with late-onset MG and higher MG-ADL scores.
-
Nationwide study shows racial and ethnic differences in MG severity
People of color face a higher disease burden and more severe hospital outcomes from myasthenia gravis compared to white patients.
